Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Phase II, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05132777
• Other study ID #: JMT101-CSP-003
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: November 20, 2021
• Est. completion date: September 30, 2024

Study information

• Verified date: November 2021
• Source: Shanghai JMT-Bio Inc.
• Contact: Xiugao Yang
• Phone: +86-21-60677906
• Email: yangxiugao[@]mail.ecspc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 155
• Est. completion date: September 30, 2024
• Est. primary completion date: September 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age=18 years.

2. Patients with non-irradiable, non-operable, histologically or cytologically confirmed Stage IIIB~IV NSCLC, harboring an EGFR exon 20 insertion mutation (including duplication mutations), who have progressed on or intolerable to prior platinum-based chemotherapy.

3. At least 1 measurable lesion according to RECIST 1.1.

4. ECOG score 0 or 1.

5. Life expectancy=3 months.

6. Adequate organ function(tested within 7 days prior to the first dose): Absolute neutrophil count (ANC)=1.5×10^9 /L, Platelets=90×10^9/L, Hemoglobin=9 g/dL or =5.6 mmol/L; Serum creatinine <1.5 × ULN; Total bilirubin =1.5×ULN (if liver metastases are present,=3×ULN), AST and ALT=3×ULN (if liver metastases are present,=5×ULN);INR or PT=1.5×ULN, APTT=1.5×ULN.

7. A female of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose. Any male and female patient of childbearing potential must agree to use effective contraception method throughout the trial period and for another half year after the end of the trial.

8. Fully understand and fully informed of this study; must sign and give the written Informed Consent Form (ICF).

Exclusion Criteria:

1. Previously received monoclonal antibody therapy targeting EGFR.

2. Previous chemotherapy, biotherapy, targeted therapy, immunotherapy or other anti-tumor treatment within 4 weeks prior to the first dose of the study drug, 2 weeks (or 5 half-lives whichever is longer) for using small molecule targeted drugs, 2 weeks for using radiotherapy..

3. Treated with other investigational agents within 4 weeks prior to the first dose of the study drug.

4. Experienced any major surgery (excluding puncture biopsy) or significant trauma within 4 weeks prior to the first dose.

5. Hypersensitivity or intolerance to our study drug or any excipients of the study drug.

6. Received strong or moderate inducers of CYP3A4 within 14 days prior to the first dose.

7. The adverse reactions of previous antitumor treatment have not yet recovered to Grade= 1 based on CTCAE 5.0 or baseline (except for the toxicity without safety risk judged by the investigator, such as alopecia).

8. Had untreated central nervous system metastasis or meningeal metastasis.

9. History of autoimmune disease, immunodeficiency, including HIV positive, or the presence of other acquired or congenital immunodeficiency, or organ transplantation.

10. Active hepatitis B, hepatitis C virus or syphilis infection.

11. History of severe cardiovascular disease.

12. Have difficulty with swallowing medications, or there is a condition seriously affecting the gastrointestinal absorption as judged by investigators.

13. Other malignant tumors diagnosed within 5 years prior to the first dose, with the exception of adequately treated skin basal cell carcinoma, skin squamous cell carcinoma, preinvasive cervical carcinoma or breast cancer that was effectively removed and not requiring or not expected to require other treatment during the study period.

14. History of interstitial lung disease, drug-induced interstitial lung disease, radioactive pneumonia requiring steroid treatment, or any evidence of clinical active interstitial lung disease.

15. History of other serious systemic diseases, in the judgment of the investigator, that make the subject unfit for the study.

16. Alcohol or drug dependence.

17. Had an unequivocal history of neurological or psychiatric disorders, including epilepsy or dementia.

18. Pregnant or lactating woman.

19. Not suitable for this study as determined by the investigator due to other reasons.

20. Patients harboring EGFR exon20 insertion mutation and also have other EGFR TKI-sensitizing EGFR mutations, such as G719X mutation in exon 18, exon 19 deletion mutation (19 del), exon 20 T790M or S768I mutation, exon 21 L858R mutation, or L861Q mutation.

21. Previously received drugs that developed for EGFR exon20 insertion mutated NSCLC ( such as TAK-788, Poziotinib, DZD9008 or JNJ-61186372); the short-term use is allowed, such as=2 weeks. Responsive to previous EGFR-TKI treatment (including the best overall response of complete response, partial response, or stable disease last more than 6 months). Previously received PD-1 or PD-L1 monoclonal antibody therapy within 3 months prior to the first dose.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• JMT101
JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
• Osimertinib Mesylate Tablets
Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai JMT-Bio Inc.	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Confirmed Objective Response Rate (ORR) Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1		From the first dose to disease progression or end of study, an average of 1 year
Secondary	Confirmed ORR Assessed by the Investigator per RECIST Version 1.1		From the first dose to disease progression or end of study, an average of 1 year
Secondary	Duration of Response (DoR)		From the first dose to disease progression or end of study, an average of 1 year
Secondary	Disease control rate (DCR)		From the first dose to disease progression or end of study, an average of 1 year
Secondary	Progression free survival (PFS)		From the first dose to disease progression or end of study, an average of 1 year
Secondary	Overall survival (OS)		From the first dose to death or end of study, an average of 1.5 years
Secondary	Incidence of adverse events (defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAEV5.0))		From the enrollment until 30 days after the last dose
Secondary	Immunogenicity profile of JMT101	Blood samples will be collected at specified timepoints to detect the presence of anti-drug antibodies and neutralizing antibodies against JMT101	From the enrollment until 30 days after the last dose
Secondary	Area under the concentration curve from time 0 to the concentration at last time point (AUC0-last) of JMT101.		From the first dose to cycle 3 day 1 (each cycle is 28 days)
Secondary	Maximum measured plasma concentration (Cmax) of JMT101.		From the first dose to cycle 3 day 1 (each cycle is 28 days)
Secondary	Time to maximum plasma concentration (Tmax) of JMT101.		From the first dose to cycle 3 day 1 (each cycle is 28 days)
Secondary	Half-life (T1/2) of JMT101.		From the first dose to cycle 3 day 1 (each cycle is 28 days)
Secondary	Cl/F of JMT101.		From the first dose to cycle 3 day 1 (each cycle is 28 days)
Secondary	Detection of cancer-related biomarkers in circulating tumor DNA from plasma to analyse the corcorrelation with clinical efficacy and drug resistance.		From the enrollment to disease progression, an average of 1 year